A March 2026 policy framework from the USC Schaeffer Center warns that gene therapy costs, now ranging from $2.8M to $4.5M per one-time treatment, are “structurally misaligned” with employer health plan time horizons. The report finds that existing stop-loss products “address individual risks but fail to align incentives systemwide.” With more than 40 FDA-approved gene therapies on the market and the eligible patient pool projected to grow roughly 300% through 2026, self-insured plans face a category of catastrophic single-claimant exposure that did not exist in their historical loss triangles.
The five most expensive drugs in 2024 were all gene therapies. Casgevy (sickle cell disease) costs $3.1M, Lyfgenia (sickle cell) costs $3M, and Zynteglo (beta thalassemia) costs $2.8M per treatment. These are real claims hitting real plans, not pipeline speculation.
Who It Affects
Self-insured employer health plans are the primary exposure, particularly those with 500 or more covered lives in regions with higher sickle cell or hemophilia prevalence. Plans with specific stop-loss attachment points in the typical $250K to $500K range will see any gene therapy claim immediately pierce the specific layer, shifting recovery to the stop-loss carrier. But the carrier knows this too: traditional stop-loss markets are increasingly excluding conditions known to be eligible for gene therapy (sickle cell, hemophilia, beta thalassemia), shifting the full cost back to the plan sponsor even when stop-loss is nominally in place.
The Reserve Mechanism
The core risk is severity, compounded by aggregate corridor stress. A single $3M gene therapy claim in a plan year can represent 5% to 15% of total expected claims for a mid-sized self-insured group. If the plan’s expected claim ratio was set using historical experience that contains zero gene therapy claims, the ratio understates the tail. One claim is a shock; two in the same plan year can exhaust the aggregate stop-loss corridor entirely.
This is not a gradual trend shift. Gene therapy claims arrive as binary events: either a covered member receives a $3M treatment or they do not. There is no partial severity. That binary profile makes traditional development-based methods less useful for projecting gene therapy exposure, because there is no historical development pattern to extend. Plans need an explicit loading factor layered into the expected claim ratio, similar to catastrophe loads in property insurance.
The USC Schaeffer report highlights a second structural problem: employer plan horizons run 3 to 5 years, but gene therapy benefits span decades. A plan pays the full $3M upfront for a cure the employee may carry to a future employer. That mismatch means the plan bears 100% of the cost and captures a fraction of the savings, which further distorts any cost-benefit analysis used to justify coverage.
Standalone gene therapy stop-loss products are emerging to fill the gap. BCS Financial now offers two products for 2026 plan years: Stop Loss GT for groups of 3,000 or more lives (standalone coverage), and Stop Loss GTS for groups of 101 or more that already carry traditional stop-loss (a carve-out complement). Amwins has a similar gene therapy solutions program. These products exist precisely because the traditional stop-loss market is retreating from the risk.
What to Ask Your Actuary
- Does our current aggregate stop-loss corridor include a gene therapy loading factor? If not, what would adding one do to our expected claim ratio and renewal pricing?
- Has our stop-loss carrier added gene therapy exclusions or lasering provisions at the last renewal? If so, what is our uninsured exposure to a single claim above $3M?
- Should we model a gene therapy carve-out (like BCS’s standalone product) against our current stop-loss structure to determine which approach provides better aggregate protection for our population?
What to Watch Next
The next wave of FDA approval decisions in late 2026 and 2027, particularly for hemophilia and Duchenne muscular dystrophy gene therapies, will expand the eligible patient pool and increase the probability of a claim hitting any individual self-insured plan. Watch whether major stop-loss carriers begin standardizing gene therapy exclusions at renewal. If exclusions become market-standard, the uninsured exposure gap for self-insured plans without a standalone carve-out will widen materially, and reserve assumptions built on historical experience alone will understate the liability.